EyePoint Pharmaceuticals, Inc. (EYPT) Key Metrics
EYPT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $250.7M
- Enterprise value
- $160.1M
- P/E (TTM)
- —
- Forward P/E
- 6.2
- PEG ratio
- —
- Price / sales
- 89.9 10-yr median 9.7
- Price / book
- 2.1 10-yr median 1.9
- EV / EBITDA
- 11.6
- Dividend yield
- —
- Beta
- 1.68
EYPT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsEYPT valuation Price multiples at each fiscal year-end price.
Price / sales+340.1%
42.7
2025 · hover or tap a bar for each year
20162025
Price / book+250.8%
4.4
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+12.9 pts
−18.2%
2025 · hover or tap a bar for each year
20162025
EYPT returns How much profit the business earns on the capital it uses.
Return on equity−28.8 pts
−72.2%
2025 · hover or tap a bar for each year
20162025
Return on assets−25.5 pts
−59.3%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin−474.8 pts
−775.8%
2025 · hover or tap a bar for each year
20162025
Asset turnover−28.3%
0.08
2025 · hover or tap a bar for each year
20162025
EYPT per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−44.3%
$0.43
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$3.17
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$3.32
2025 · hover or tap a bar for each year
20162025
Book value per share−30.1%
$4.18
2025 · hover or tap a bar for each year
20162025
Shares outstanding+30.1%
73.3M
2025 · hover or tap a bar for each year
20162025
EYPT financial health Debt, liquidity and how easily interest is covered.
Debt / equity+14.6%
0.07
2025 · hover or tap a bar for each year
20162025
Net debt+$65.8M
−$283.3M
2025 · hover or tap a bar for each year
20162025
Current ratio+13.6%
8.88
2025 · hover or tap a bar for each year
20162025
Debt / assets+19.9%
0.06
2025 · hover or tap a bar for each year
20162025
EYPT efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+1 days
7 days
2025 · hover or tap a bar for each year
20162025
Days of inventory+58 days
364 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+1,066 days
1,962 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−1,006 days
-1,591 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+1.1 pts
10.5%
2025 · hover or tap a bar for each year
20162025
EYPT valuation history
Fiscal year-endToday10-year median
EYPT returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
EYPT debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
EYPT cash returned to shareholders
DividendsBuybacksFree cash flow
EYPT price vs earnings per share
Share price at year-endEPS (right axis)
EYPT key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.34B | $419.4M | $899.1M | $130.6M | $352.0M | — | — | — | — | — |
| Enterprise value | $1.06B | $70.4M | $572.9M | $32.4M | $179.6M | — | — | — | — | — |
| Price / sales | 42.7 | 9.7 | 19.5 | 3.2 | 9.5 | — | — | — | — | — |
| Price / book | 4.4 | 1.2 | 3.4 | 1.4 | 1.9 | — | — | — | — | — |
| Price / operating cash flow | — | — | 479.5 | — | — | — | — | — | — | — |
| EV / sales | 33.6 | 1.6 | 12.5 | 0.8 | 4.9 | — | — | — | — | — |
| Earnings yield | −17.3% | −31.2% | −7.9% | −78.3% | −16.6% | — | — | — | — | — |
| Free cash flow yield | −18.2% | −31.1% | −0.2% | −51.4% | −14.3% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 0.0% | 0.2% | 0.0% | — | — | — | — | — |
| Share price at fiscal year-end | $18.27 | $7.45 | $23.11 | $3.50 | $12.24 | $6.58 | $15.50 | $18.90 | $10.80 | $17.10 |
| Per share | ||||||||||
| Revenue per share | $0.43 | $0.77 | $1.18 | $1.11 | $1.28 | — | — | — | — | — |
| Earnings per share | −$3.17 | −$2.32 | −$1.82 | −$2.74 | −$2.03 | — | — | — | — | — |
| Operating cash flow per share | −$3.28 | −$2.24 | $0.05 | −$1.74 | −$1.74 | — | — | — | — | — |
| Free cash flow per share | −$3.32 | −$2.31 | −$0.04 | −$1.80 | −$1.75 | — | — | — | — | — |
| Cash per share | $4.18 | $6.59 | $8.51 | $3.87 | $7.36 | — | — | — | — | — |
| Book value per share | $4.18 | $5.98 | $6.85 | $2.58 | $6.41 | — | — | — | — | — |
| Tangible book value per share | $4.18 | $5.98 | $6.85 | $2.58 | $5.62 | — | — | — | — | — |
| Capex per share | $0.04 | $0.07 | $0.09 | $0.06 | $0.01 | — | — | — | — | — |
| Debt per share | $0.31 | $0.39 | $0.13 | $1.24 | $1.36 | — | — | — | — | — |
| Shares outstanding | 73.3M | 56.3M | 38.9M | 37.3M | 28.8M | — | — | — | — | — |
| Change in shares outstanding | +30.1% | +44.7% | +4.3% | +29.8% | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −72.2% | −43.4% | −39.0% | −72.8% | −57.6% | −337.9% | −567.4% | −425.0% | −138.6% | −125.9% |
| Return on invested capital (ROIC) | — | — | — | — | −272.2% | −103.8% | −277.2% | — | −288.2% | — |
| Return on assets (ROA) | −59.3% | −33.8% | −26.4% | −46.1% | −32.9% | −55.1% | −78.5% | −117.7% | −99.0% | −84.4% |
| Return on tangible assets | −63.7% | −31.3% | −19.9% | −56.7% | −24.3% | −68.3% | −125.4% | −131.9% | −100.9% | −122.6% |
| Free cash flow margin | −775.8% | −301.1% | −3.5% | −162.2% | −136.0% | −43.0% | −279.5% | −375.9% | −273.7% | — |
| Financial health | ||||||||||
| Total debt | $22.8M | $21.9M | $4.9M | $46.3M | $39.2M | $46.4M | $50.6M | $17.7M | $17.3M | $0 |
| Cash & short-term investments | $306.1M | $370.9M | $331.1M | $144.6M | $211.6M | $44.9M | $22.2M | $38.8M | $16.9M | $16.9M |
| Net debt | −$283.3M | −$349.1M | −$326.1M | −$98.2M | −$172.4M | $1.5M | $28.4M | −$21.1M | $411,000 | −$16.9M |
| Debt / equity | 0.07 | 0.06 | 0.02 | 0.48 | 0.21 | 2.50 | 6.07 | 1.51 | 1.30 | 0.00 |
| Debt / assets | 0.06 | 0.05 | 0.01 | 0.26 | 0.15 | 0.51 | 0.69 | 0.25 | 0.93 | 0.00 |
| Current ratio | 8.88 | 7.81 | 5.45 | 5.00 | 10.05 | 4.24 | 3.62 | 1.84 | 3.35 | 3.35 |
| Quick ratio | 8.83 | 7.77 | 5.39 | 4.92 | 9.90 | 3.88 | 3.44 | 1.86 | 3.40 | 3.45 |
| Interest coverage | — | — | -60.2 | -31.2 | -10.1 | -5.1 | -7.7 | -68.2 | -25.8 | — |
| Working capital | $291.6M | $334.3M | $281.5M | $138.3M | $214.1M | $48.2M | $30.2M | $18.2M | $12.4M | $12.4M |
| Invested capital | $22.8M | −$12.6M | −$59.8M | −$1.8M | $12.0M | $20.1M | $36.7M | −$9.4M | $13.7M | −$3.6M |
| Tangible asset value | $306.1M | $336.5M | $266.3M | $96.4M | $161.6M | −$6.7M | −$19.3M | −$19.7M | $13.0M | $12.2M |
| Net current asset value | $270.8M | $301.3M | $255.9M | $88.8M | $158.8M | −$10.1M | −$22.9M | −$20.1M | $12.4M | $12.4M |
| Graham net-net per share | $3.41 | $5.16 | $6.29 | $1.97 | $5.15 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | $169,000 | $295,000 | $150,000 | $90,000 | $131,000 | $195,000 | $0 | $0 |
| Capex / revenue | 10.5% | 9.4% | 7.6% | 5.2% | 0.4% | 1.1% | 1.0% | 1.8% | 1.9% | 7.0% |
| Capex / operating cash flow | — | — | 185.8% | — | — | — | — | — | — | — |
| Capex / depreciation | 1.42 | 2.63 | 7.51 | 0.88 | 0.06 | 0.14 | 0.08 | 0.04 | 0.18 | 0.14 |
| Stock-based compensation / revenue | 88.8% | 84.9% | 26.2% | 34.2% | 20.2% | 16.1% | 22.4% | 67.7% | 32.6% | 151.6% |
| R&D / revenue | 704.6% | 307.2% | 140.5% | 119.9% | 77.2% | 50.6% | 75.5% | 355.6% | 197.4% | 887.7% |
| SG&A / revenue | 164.8% | 121.3% | 112.5% | 145.7% | 143.7% | 133.6% | 234.3% | 428.4% | 149.0% | 556.4% |
| Efficiency | ||||||||||
| Days sales outstanding | 7.3 | 6.0 | 64.7 | 149.2 | 137.4 | 110.3 | 105.0 | 18.8 | 12.2 | 83.3 |
| Days of inventory on hand | 363.8 | 305.4 | 267.6 | 142.5 | 199.8 | 234.2 | 121.2 | -6.0 | -8.3 | -13.6 |
| Days payables outstanding | 1,962.0 | 896.0 | 489.5 | 291.6 | 272.2 | 282.1 | 737.3 | 75.7 | 22.9 | 29.2 |
| Cash conversion cycle (days) | -1,590.9 | -584.7 | -157.2 | 0.1 | 65.0 | 62.5 | -511.0 | -62.9 | -19.1 | 40.5 |
| Receivables turnover | 49.87 | 61.29 | 5.64 | 2.45 | 2.66 | 3.31 | 3.47 | 19.39 | 30.04 | 4.38 |
| Payables turnover | 0.19 | 0.41 | 0.75 | 1.25 | 1.34 | 1.29 | 0.50 | 4.82 | 15.92 | 12.51 |
| Inventory turnover | 1.00 | 1.20 | 1.36 | 2.56 | 1.83 | 1.56 | 3.01 | — | — | — |
| Asset turnover | 0.08 | 0.11 | 0.17 | 0.19 | 0.21 | 0.42 | 0.28 | 0.13 | 0.40 | 0.06 |
| Average receivables | $629,000 | $706,000 | $8.2M | $16.9M | $13.9M | $10.4M | $5.9M | $302,000 | $251,000 | $369,500 |
| Average payables | $11.1M | $9.1M | $6.2M | $6.7M | $6.1M | $4.5M | $5.4M | $3.8M | $1.0M | $1.2M |
| Average inventory | $2.1M | $3.1M | $3.4M | $3.3M | $4.5M | $3.7M | $892,500 | −$302,000 | −$369,500 | −$555,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 8.6% | 27.5% | 37.9% | 43.8% | 1.9% | 5.9% |
Computed from EYPT's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
EYPT valuation and financial ratios
EyePoint Pharmaceuticals earned a return on equity of −72.2% in fiscal 2025. It ended the year with $22.8 million of debt and $306.1 million in cash and short-term investments, a net cash position of $283.3 million.
See the EYPT income statement, the EYPT chart for price history, or the EYPT stock overview for the latest quote and news.
EYPT key metrics FAQ
What is EyePoint Pharmaceuticals's return on equity?
EyePoint Pharmaceuticals's return on equity (ROE) was −72.2% in fiscal 2025: net income of -$232.0 million on average shareholders' equity of $321.3 million.
How much debt does EyePoint Pharmaceuticals have?
EyePoint Pharmaceuticals had total debt of $22.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.07 and more cash than debt.
What is EyePoint Pharmaceuticals's free cash flow yield?
EyePoint Pharmaceuticals generated -$243.4 million of free cash flow in fiscal 2025, a free cash flow yield of −18.2% on its market value at year-end ($1.3 billion).
What is EyePoint Pharmaceuticals's current ratio?
EyePoint Pharmaceuticals's current ratio was 8.88 at the end of fiscal 2025: current assets were 8.88 times current liabilities.